Selectivity

Selectivity is the degree to which a substance acts on one molecular target — a receptor subtype, enzyme, or transporter — relative to others it could physically reach. A drug with high selectivity concentrates its effect through a narrow, well-defined pathway; one with low selectivity engages a wider range of targets, producing a broader and more complex effect profile.

Selectivity is not fixed. Even a compound considered highly selective at typical doses may begin acting on secondary targets at higher concentrations. This is one reason dose escalation can produce qualitatively different effects rather than simply more of the same.

How it works · its role

Biological targets — receptors, enzymes, transporters — each have a distinct three-dimensional structure. A drug binds to targets whose shape complements its own, and selectivity describes how differently it binds across a family of related targets.

Affinity and selectivity are related but distinct. Affinity measures how tightly a molecule binds to any one target; selectivity measures how much that binding preference varies across several targets. A highly selective compound may have strong affinity for one receptor subtype and near-zero affinity for closely related subtypes within the same family.

A low-selectivity compound — sometimes called a multi-target drug, or informally a dirty drug — occupies many receptors at once. This produces a more complex pharmacological signature that can be harder to predict and harder to reverse.

Relevance to substances & effects

The word selective appears directly in several well-known drug class names. SSRIs — selective serotonin reuptake inhibitors — are designed to target the SERT while leaving norepinephrine and dopamine transporters largely untouched, distinguishing them from older antidepressants that act broadly across all three.

Classic psychedelics such as LSD and psilocin act primarily at 5-HT₂A serotonin receptors, but their full effect signature reflects binding across multiple serotonin subtypes in different proportions — one reason different psychedelics feel qualitatively distinct despite sharing the same general mechanism.

Opioids offer a clear within-class illustration. Compounds that strongly prefer the μ-opioid tend to produce pain suppression and euphoria; those with greater selectivity for the kappa receptor tend to produce dysphoria and perceptual disturbances instead.

Low selectivity multiplies interaction risk. When a substance engages many targets simultaneously, predicting how it will behave alongside another drug becomes harder, because each target is an additional collision point with other substances acting on the same system.